Generally, applicable endocrine treatment for ERα-positive breast cancer has been usually adopted by using ERα inhibitors, including selective ERα modulators (such as Tamoxifen), aromatase inhibitors (such as Letrozole) and selective ERα degraders (such as Fulvestrant) in clinical therapy. This evidence concerns the gene ESR1 and breast carcinoma.